Zimmer Biomet Holdings Inc (NYSE:ZBH) – Stock analysts at Jefferies Group dropped their FY2017 earnings estimates for Zimmer Biomet Holdings in a note issued to investors on Wednesday. Jefferies Group analyst R. Denhoy now expects that the medical equipment provider will post earnings of $8.03 per share for the year, down from their prior forecast of $8.24. Jefferies Group has a “Buy” rating and a $136.00 price objective on the stock. Jefferies Group also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.10 EPS, Q1 2018 earnings at $2.04 EPS, Q2 2018 earnings at $2.02 EPS, Q3 2018 earnings at $1.94 EPS, Q4 2018 earnings at $2.25 EPS and FY2018 earnings at $8.25 EPS.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The firm had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter last year, the firm earned $1.79 EPS. The company’s revenue was down .8% on a year-over-year basis.
ILLEGAL ACTIVITY WARNING: “Jefferies Group Weighs in on Zimmer Biomet Holdings Inc’s FY2017 Earnings (ZBH)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/11/04/jefferies-group-weighs-in-on-zimmer-biomet-holdings-incs-fy2017-earnings-zbh.html.
A number of other analysts have also recently commented on the stock. Stifel Nicolaus restated a “hold” rating and set a $120.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday. Morgan Stanley dropped their price target on shares of Zimmer Biomet Holdings from $146.00 to $136.00 and set an “overweight” rating on the stock in a research note on Thursday. BMO Capital Markets dropped their price target on shares of Zimmer Biomet Holdings from $140.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday. Piper Jaffray Companies cut shares of Zimmer Biomet Holdings from an “overweight” rating to a “neutral” rating in a research note on Thursday. Finally, SunTrust Banks, Inc. set a $136.00 price target on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings has an average rating of “Hold” and an average target price of $134.75.
Zimmer Biomet Holdings (NYSE ZBH) opened at $109.25 on Thursday. The firm has a market cap of $22.09 billion, a price-to-earnings ratio of 13.92, a price-to-earnings-growth ratio of 1.53 and a beta of 1.17. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.80 and a current ratio of 1.47. Zimmer Biomet Holdings has a 1 year low of $95.63 and a 1 year high of $133.49.
Large investors have recently modified their holdings of the company. MARSHALL WACE ASIA Ltd bought a new position in shares of Zimmer Biomet Holdings in the 1st quarter worth $38,621,000. Ingalls & Snyder LLC boosted its stake in shares of Zimmer Biomet Holdings by 2.6% in the 3rd quarter. Ingalls & Snyder LLC now owns 19,675 shares of the medical equipment provider’s stock valued at $2,304,000 after purchasing an additional 507 shares in the last quarter. Caxton Associates LP purchased a new stake in shares of Zimmer Biomet Holdings in the 1st quarter valued at $403,000. Koch Industries Inc. boosted its stake in shares of Zimmer Biomet Holdings by 49,697.3% in the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after purchasing an additional 1,038,674 shares in the last quarter. Finally, Jensen Investment Management Inc. boosted its stake in shares of Zimmer Biomet Holdings by 24.2% in the 2nd quarter. Jensen Investment Management Inc. now owns 5,850 shares of the medical equipment provider’s stock valued at $751,000 after purchasing an additional 1,140 shares in the last quarter. 85.26% of the stock is currently owned by hedge funds and other institutional investors.
The business also recently declared a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 22nd were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend was Thursday, September 21st. Zimmer Biomet Holdings’s payout ratio is 29.91%.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc and related companies.